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Transport-Dependent Proteolysis of SREBP:
Relocation of Site-1 Protease from Golgi to ER
Obviates the Need for SREBP Transport to Golgi
complex is formed by an interaction between the cyto-
solic COOH-terminal regulatory domain of the SREBPs
and the cytosolic WD40 domain of SCAP. SCAP targets
the SREBPs to S1P, a membrane-bound serine protease
whose active site faces the lumen of the ER and post-
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ER organelles (Sakai et al., 1998b). S1P cleaves theSouthwestern Medical Center
luminal loop of the SREBPs following the tetrapeptideDallas, Texas 75390-9046
sequence Arg-Xaa-Xaa-Leu, thereby separating SREBP
into two halves (Duncan et al., 1997). This event allows
a second protease, designated Site-2 protease (S2P),Summary
to cleave the NH2-terminal transmembrane domain,
thereby liberating the NH2-terminal segments of SREBPsCholesterol homeostasis in animal cells is achieved by
from the membrane and allowing them to enter the nu-regulated cleavage of membrane-bound transcription
cleus (Sakai et al., 1996; Rawson et al., 1997).factors, designated SREBPs. Proteolytic release of the
This complex proteolytic activation mechanism allowsactive domains of SREBPs from membranes requires a
lipid synthesis to be controlled by the lipid content of cellsterol-sensing protein, SCAP, which forms a complex
membranes (Brown and Goldstein, 1997). When cells arewith SREBPs. In sterol-depleted cells, SCAP escorts
depleted of sterols, the cleavage reactions are rapid,SREBPs from ER to Golgi, where SREBPs are cleaved
and the NH2-terminal segments of SREBPs readily enterby Site-1 protease (S1P). Sterols block this transport
the nucleus. When cells are overloaded with sterols, theand abolish cleavage. Relocating active S1P from
Site-1 cleavage reaction is blocked. The SREBPs remainGolgi to ER by treating cells with brefeldin A or by
bound to cell membranes, and the target genes are nofusing the ER retention signal KDEL to S1P obviates
longer activated. Cholesterol synthesis stops as a resultthe SCAP requirement and renders cleavage insensi-
of decreased transcription of genes encoding 3-hydroxy-tive to sterols. Transport-dependent proteolysis may
3-methylglutaryl coenzyme A (HMG CoA) synthase,be a common mechanism to regulate the processing
HMG CoA reductase, and other enzymes of the cho-of membrane proteins.
lesterol biosynthetic pathway. Cholesterol uptake is
blocked by a downregulation of the low-density lipopro-Introduction
tein (LDL) receptor, and the synthesis of unsaturated
fatty acids is partially decreased as a result of reducedCleavage of sterol regulatory element binding proteins
transcription of genes encoding acetyl CoA carboxyl-(SREBPs) by Site-1 protease (S1P) initiates a process by
ase, fatty acid synthase, and stearoyl CoA desaturasewhich the active fragments of the SREBPs translocate to
(Brown and Goldstein, 1997; Edwards and Ericsson,the nucleus and activate genes controlling the synthesis
1999).and uptake of cholesterol and unsaturated fatty acids
Biochemical and genetic data show that SCAP is thein animal cells (Brown and Goldstein, 1999). The SREBPs
key to the regulation of Site-1 cleavage (Hua et al.,are synthesized as tripartite membrane-bound proteins
1996a; Nohturfft et al., 1996, 1999; Rawson et al., 1999).averaging 1150 amino acids in length. The NH2-terminal Mutant Chinese hamster ovary (CHO) cells that lacksegment of z480 amino acids is a transcription factor
SCAP fail to cleave SREBPs at Site-1, and they areof the basic helix-loop-helix-leucine zipper (bHLH-Zip)
therefore auxotrophic for cholesterol and unsaturated
family. This is followed by an 80±amino acid membrane
fatty acids (Rawson et al., 1999). Sterols block Site-1
attachment domain that comprises two transmembrane
cleavage by reducing the activity of SCAP. This inhibi-
helices separated by a short hydrophilic loop of z30 tion does not occur when SCAP bears substitution muta-
amino acids. This is followed by a COOH-terminal regu- tions at either of two positions in its membrane attach-
latory domain of z590 amino acids. Newly synthesized ment domain (Tyr298Cys or Asp443Asn) (Hua et al.,
SREBPs are bound to membranes of the nuclear enve- 1996a; Nohturfft et al., 1996, 1998b). This portion of the
lope and endoplasmic reticulum (ER) in a hairpin fashion membrane attachment domain has been designated the
with the NH2-terminal and COOH-terminal segments sterol-sensing region. Mutant CHO cells that produce
projecting into the cytosol and the hydrophilic loop pro- these altered forms of SCAP overproduce cholesterol
jecting into the lumen (Brown and Goldstein, 1997). and fail to slow this synthesis when cholesterol overac-
The newly synthesized SREBPs form complexes with cumulates in the cell.
a polytopic membrane protein designated SCAP (SREBP Evidence indicates that SCAP acts by escorting
cleavage-activating protein) (Sakai et al., 1997, 1998a). SREBPs to a post-ER compartment where the active
The NH2-terminal domain of SCAP contains eight trans- S1P resides and that sterols may prevent cleavage by
membrane helices, and the COOH-terminal domain con- blocking this transport (Nohturfft et al., 1998b, 1999).
tains five WD40 repeats that mediate protein±protein This hypothesis emerged from studies of the N-linked
interactions (Nohturfft et al., 1998a). The SREBP/SCAP carbohydrates attached to a luminal loop in the poly-
topic membrane domain of SCAP. When cells are de-
pleted of sterols, these carbohydrates are largely resis-* To whom correspondence should be addressed (e-mail: mbrow1@
mednet.swmed.edu [M. S. B.], jgolds@mednet.swmed.edu [J. L. G.]). tant to cleavage by endoglycosidase H (endo H),
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indicating that SCAP has reached the Golgi apparatus
where it has been modified by Golgi mannosidase II
(Kornfeld and Kornfeld, 1985). When cells are over-
loaded with sterols, the N-linked sugars of SCAP remain
in an endo H±sensitive form, indicating that SCAP has
not reached the Golgi. In sterol-depleted cells, most of
the SCAP cofractionates with ER markers even though
it has been modified by Golgi enzymes (Nohturfft et al.,
1999). These findings have led to a model in which SCAP
carries SREBP from the ER to the Golgi in sterol-
depleted cells, after which SCAP recycles to the ER
following Site-1 cleavage. In sterol-overloaded cells, the
SCAP/SREBP complex does not leave the ER and Site-1
Figure 1. Brefeldin A Blocks Sterol-Mediated Suppression ofcleavage cannot take place.
SREBP Cleavage in CHO Cells
A corollary of the sterol-regulated cycling model is
On day 0, CHO-7 cells were set up at 5 3 105 cells per 10 cm dishthat S1P is not active in the ER and that it becomes
in medium A supplemented with 5% fetal calf serum. On day 2, the
activated only after transport to a post-ER compart- cells were switched to medium A supplemented with 5% newborn
ment. Partial support for this model comes from experi- calf lipoprotein-deficient serum and compactin/mevalonate in the
absence (A) or presence (B) of sterols. After 16 hr, the cells werements on the activation process of S1P. S1P, like other
switched to medium A supplemented with 5% newborn calf lipopro-mammalian subtilases, is synthesized in the ER as an
tein-deficient serum and compactin/mevalonate in the absence orinactive precursor (Espenshade et al., 1999). It becomes
presence of sterols and 1 mg/ml brefeldin A as indicated. After 5active only after it is autocatalytically cleaved, liberating
hr, the cells were harvested, and membrane and nuclear extract
an NH2-terminal propeptide. Most of the inactive S1P fractions were prepared as described in the Experimental Proce-
precursor, designated S1P-A, is endo H sensitive, sug- dures. Aliquots of the membranes (50 mg protein) and nuclear ex-
tracts (100 mg protein) were subjected to SDS-PAGE. Immunoblotgesting that the protein is largely located in the ER. On
analysis was performed with 5 mg/ml of monoclonal IgG-7D4, whichthe other hand, the major active form of S1P, designated
recognizes SREBP-2. The filters were exposed to Kodak X-OmatS1P-C, is endo H resistant, suggesting that it resides in
Blue XB-1 film for 10 s (membranes) and 1 min (nuclear extracts) atthe Golgi (Espenshade et al., 1999).
room temperature. P, I, and N denote the precursor, intermediate,
If the primary function of SCAP is to transport SREBP and nuclear forms of SREBP, respectively.
to the post-ER compartment that contains active S1P,
the requirement for SCAP should be abolished if we
could generate active S1P in the ER. The current experi- incubated in the absence of sterols (lower panel, lane
ments were designed to test this hypothesis using mu- 1) but not in the presence of sterols (lane 2). When the
tant SRD-13A cells that lack SCAP (Rawson et al., 1999). final 5 hr incubation was conducted in the presence of
We used two approaches to trap active S1P in the ER. brefeldin A, nuclear SREBP-2 continued to be visualized
First, we treated the SRD-13A cells with brefeldin A, an in the sterol-depleted cells (lane 3), but there was no
agent that blocks anterograde movement of proteins longer any decrease when sterols were added (lane 4).
from ER to Golgi, thus causing Golgi proteins to translo- The amount of the membrane-bound precursor did not
cate back to the ER (Lippincott-Schwartz et al., 1989). change under any of these conditions (upper panel).
Second, we transfected the SRD-13A cells with a cDNA Brefeldin A did produce an increase in the membrane-
encoding a truncated, soluble luminal form of S1P with bound intermediate of SREBP (designated I in Figure
an ER retention signal inserted at its COOH terminus. 1), which is the immediate product of Site-1 cleavage.
Both of these treatments led to Site-1 cleavage of This experiment shows that brefeldin A blocks the sup-
SREBPs in the SCAP-deficient SRD-13A cells, and in pression of Site-1 cleavage by sterols.
both cases this SCAP-independent cleavage was not Panel B of Figure 1 shows that brefeldin A induces
inhibited by sterols. These data provide strong experi- SREBP cleavage in cells that were previously inhibited
mental support for the sterol-regulated transport model by sterols. In this experiment, the cells were incubated
of SCAP function. for 16 hr in the presence of sterols, and then some of
the dishes were switched to sterol-free medium in the
absence or presence of brefeldin A. In the absence ofResults
brefeldin A, we found no nuclear SREBP-2 in the sterol-
treated cells (panel B, lane 2). In the presence of brefel-Figure 1 shows an experiment designed to test the ef-
fects of brefeldin A on sterol-regulated cleavage of din A, nuclear SREBP-2 appeared even when sterols
were present (lane 4). Again, brefeldin A blocked sterolSREBP-2 in wild-type CHO-7 cells. In panel A, the cells
were incubated for 16 hr without sterols to induce cleav- suppression of SREBP cleavage.
A trivial explanation for the findings in Figure 1 wouldage of SREBPs. The cells were then incubated for an
additional 5 hr in the absence or presence of a mixture of exist if brefeldin A blocked the movement of the exoge-
nous sterols to the ER. This possibility is rendered un-25-hydroxycholesterol and cholesterol, which efficiently
suppresses Site-1 cleavage. Extracts of cell membranes likely by the prior findings of Ridgway and Lagace (1995),
who showed that brefeldin A does not interfere withand nuclei were then subjected to SDS-PAGE and blot-
ted with an antibody against the NH2-terminal segment the ability of 25-hydroxycholesterol to stimulate the ER
synthesis of cholesteryl esters in CHO cells. This resultof SREBP-2. As expected, the NH2-terminal segment
was found in the nuclear extract when the cells were was confirmed in our laboratory (Nohturfft et al., 1999).
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Figure 2. Brefeldin A Induces S1P-Depen-
dent Cleavage of SREBPs in Transfected
Cells
(A) On day 0, SCAP-deficient SRD-13A cells
were set up at a density of 4 3 105 cells/60
mm dish in medium B. On day 1, cells were
transfected with 2 mg/dish of pTK-HSV-BP2
together with 0.25 mg/dish pTK-SCAP. The
total amount of DNA was adjusted to 4 mg/
dish with pcDNA3 empty vector and pTK
mock vector. On day 2, the cells were cultured
for 16 hr in medium A supplemented with 5%
newborn calf lipoprotein-deficient serum and
compactin/mevalonate in the absence or
presence of sterols. On day 3, cells were incu-
bated with or without 1 mg/ml brefeldin A for
5 hr, after which they were harvested and
fractionated as described in Figure 1. Ali-
quots of membranes (6 mg protein) and nuclear extracts (10 mg protein) were subjected to SDS-PAGE, and immunoblot analysis was carried
out with 0.1 mg/ml of IgG-HSV-Tag for pTK-HSV-BP2 and 5 mg/ml IgG-R139 for SCAP. Filters were exposed to film for 1 s (top and bottom
panels) and 30 s (middle panel). Molecular mass standards are expressed in kilodaltons.
(B) On day 0, S1P-deficient SRD-12B cells were set up at a density of 3 3 105 cells/60 mm dish in medium B. On day 1, cells were transfected
with 2 mg/dish of pTK-HSV-BP2 together with 0.5 mg/dish pCMV-Myc-S1P. The total amount of DNA was adjusted to 4 mg/dish with pcDNA3
empty vector and pTK mock vector. On day 2, the cells were cultured for 16 hr in the absence or presence of sterols as described in (A). On
day 3, cells were treated with 1 mg/ml brefeldin A for 5 hr prior to harvest and fractionation. Aliquots of membranes (14 mg protein) and nuclear
extract (33 mg protein) were subjected to SDS-PAGE, and immunoblot analysis was carried out with 0.1 mg/ml of IgG-HSV-Tag for pTK-HSV-
BP2 and 0.5 mg/ml anti-Myc 9E10 for Myc-S1P. Filters were exposed to film for 5 s (top panel), 15 s (middle panel), and 1 s (bottom panel).
Molecular mass standards are expressed in kilodaltons.
If the effect of brefeldin A on SREBP cleavage is of the Golgi complex (Figure 3A). This intense staining
was absent in the SRD-12B cells (Figure 3D), indicatingcaused by relocation of active S1P to the ER, then brefel-
that it was specific for S1P. We also observed a faintdin A should relieve the requirement for SCAP. To test
reticular staining pattern that appeared nonspecificthis hypothesis, we measured the cleavage of epitope-
since it was present in the SRD-12B cells (Figure 3D)tagged SREBP-2 in transfected SRD-13A cells, which
as well as the CHO/pS2P cells (Figure 3A). Because oflack SCAP as a result of mutations in the SCAP gene
this nonspecific staining, we could not determine(Figure 2A). In the absence of SCAP and brefeldin A,
whether any S1P is located in the ER. Incubation ofthese cells showed no nuclear SREBP-2 whether incu-
cells with rhodamine-conjugated wheat germ agglutininbated in the absence or presence of sterols (middle
(WGA) stained the trans-Golgi network in the CHO/pS2Ppanel, lanes 1 and 2). Treatment with brefeldin A caused
cells (Figure 3B) and the SRD-12B cells (Figure 3E).the appearance of nuclear SREBP-2, and this was not
Overlay of the green S1P image with the red WGA imageprevented by sterols (lanes 3 and 4). As a positive control
revealed that S1P and the WGA Golgi marker colocalizedfor these experiments, we transfected the cells with a
in CHO/pS2P cells, as indicated by the merged yellowcDNA encoding wild-type SCAP (lanes 5±8). In the ab-
image (Figure 3C). No colocalization was observed insence of brefeldin A, the SCAP cDNA restored nuclear
the SRD-12B cells, which is consistent with the absenceSREBP-2, and cleavage was blocked by sterols (lanes
of S1P in these cells (Figure 3F).5 and 6). Brefeldin A allowed cleavage to persist in the
We used the same technique to trace the fate of S1Ppresence of sterols (lanes 7 and 8). To confirm that
in brefeldin A±treated CHO/pS2P cells (Figure 4). In thethe nuclear SREBP-2 resulted from cleavage by Site-1
absence of brefeldin A, the anti-S1P antibody showed
protease, we performed a similar experiment in SRD-
intense Golgi fluorescence and a small amount of reticu-
12B cells, which lack S1P as a result of mutations in the lar fluorescence (Figure 4A). When the cells were treated
S1P gene (Figure 2B). In the absence of S1P, brefeldin with brefeldin A, the Golgi fluorescence disappeared,
A failed to cause the appearance of nuclear SREBP-2 and the reticular pattern increased (Figure 4D). Staining
either in the absence or presence of sterols (middle with WGA revealed a Golgi pattern (Figure 4B), and this
panel, lanes 1±4). When we cotransfected a cDNA en- was unaffected by brefeldin A (Figure 4E). This finding
coding S1P, we restored cleavage of SREBP-2, and this is consistent with previous data showing that brefeldin
was inhibited by sterols (lanes 5 and 6). Sterol suppres- A causes the cis- and medial-Golgi to collapse into the
sion was blocked by brefeldin A (lanes 7 and 8). Thus, ER, but it does not affect the trans-Golgi (Lippincott-
treatment of SCAP-deficient cells with brefeldin A res- Schwartz et al., 1989). Overlay of the S1P and WGA
cues S1P-dependent cleavage of SREBPs. images confirmed the Golgi localization of S1P in the
To study the subcellular localization of S1P directly, untreated cells (Figure 4C), and this was abolished in
we performed double-label immunofluorescence stud- the brefeldin A±treated cells (Figure 4F). This finding
ies of CHO/pS2P cells and S1P-deficient SRD-12B cells, suggests that S1P is located in the cis- and medial-
which were derived from the CHO/pS2P cells (Figure 3). Golgi, but not in the trans-Golgi.
When stained with an antibody against S1P, the CHO/ We previously reported that S1P is processed to three
pS2P cells exhibited intense staining of a juxtanuclear forms, designated S1P-A, S1P-B, and S1P-C (Espen-
shade et al., 1999). The NH2-terminal sequences of theseorganelle whose appearance was consistent with that
Cell
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Figure 3. Endogenous S1P Localizes to the
Golgi Apparatus in CHO Cells
Wild-type CHO/pS2P cells (A±C) or S1P-defi-
cient SRD-12B cells (D±F) were grown in me-
dium B, fixed, and stained with antibodies
to S1P (A and D) or rhodamine-conjugated
wheat germ agglutinin (B and E) as described
in the Experimental Procedures. Merged im-
ages (C and F) show colocalization of S1P
and the Golgi marker, wheat germ agglutinin.
Bar, 20 mm.
proteins were examined, and this revealed that S1P-A (PNGase F), the mobility of the A and C forms increased,
indicating that both forms have N-linked sugars (Figureis the product of cleavage by signal peptidase. S1P-A
retains the propeptide, and it is enzymatically inactive. 5B, lanes 2 and 3). Endo H treatment increased the
mobility of S1P-A to approximately the same extent asS1P-B and S1P-C are produced by autocatalytic re-
moval of the propeptide, and they are enzymatically PNGase F, indicating that all of the N-linked sugars
were endo H sensitive (Figure 5B, lane 4). The smallactive. The N-linked carbohydrates on S1P-A and S1P-B
are mostly endo H sensitive, indicating that the bulk difference in mobility between PNGase F±treated and
endo H±treated S1P-A may be due to the fact that endoof these proteins have not reached the medial-Golgi.
S1P-C is endo H resistant, implying that it has reached H does not remove the asparagine-linked N-acetylglu-
cosamine whereas PNGase F does. The mobility of S1P-Cthe medial-Golgi. All of these experiments were per-
formed with transfected cells that overexpressed epi- was only partially increased by endo H, and none of
it comigrated with the PNGase F product. These datatope-tagged S1P. To confirm that these same findings
apply to endogenous S1P, we performed immunoblot- indicate that all molecules of S1P-C contain at least one
endo H±resistant carbohydrate chain, implying that thisting experiments with anti-S1P in nontransfected CHO
cells (Figure 5). As reported previously, we observed protein has reached the medial-Golgi. Similar results
were obtained when the cells were incubated with ste-S1P-A, S1P-B, and S1P- C in SRD-12B cells that overex-
press transfected S1P (Figure 5A, lane 2). In contrast, rols (Figure 5B, lanes 7±10), which is consistent with
previous evidence that sterols do not affect the autocat-the nontransfected CHO cells showed only two bands,
corresponding in size to S1P-A and S1P-C (Figure 5A, alytic processing or subcellular localization of S1P (Es-
penshade et al., 1999). Together, these data suggest thatlane 3). This indicates that S1P-C is the major form
of active S1P in nontransfected cells and that S1P-B in nontransfected cells the active form of S1P, namely
S1P-C, resides in the Golgi.becomes prominent only when the protein is overex-
pressed as a result of transfection. When CHO cell mem- In addition to brefeldin A treatment, another means
to relocate active S1P from the Golgi to the ER is tobranes were treated with peptide N-glycosidase F
Figure 4. Brefeldin A Treatment Disrupts
Golgi Localization of S1P in CHO Cells
Wild-type CHO/pS2P cells were grown in me-
dium B and cultured for 1 hr in the absence
(A±C) or presence (D±F) of 2 mg/ml brefeldin
A. Cells were fixed and stained with antibod-
ies to S1P (A and D) or rhodamine-conjugated
wheat germ agglutinin (B and E) as described
in the Experimental Procedures. Merged im-
ages (C and F) show localization of S1P and
the Golgi marker, wheat germ agglutinin. Bar,
20 mm.
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SRD-12B cells, which lack endogenous S1P, and we
isolated permanent clones of cells that grow in the ab-
sence of cholesterol as a result of expressing active
S1P.
Figure 6B shows SREBP-2 processing in the parental
SRD-12B cells and the two lines of permanent transfec-
tants, designated S1P-KDEL and S1P-KDAS. When
SRD-12B cells were incubated in the absence of sterols,
the amount of SREBP-2 precursor was relatively low,
and no cleaved nuclear SREBP-2 was visualized (Figure
6B, lane 1). Addition of sterols caused an increase in
the amount of precursor, and there was still no nuclear
SREBP-2 (lane 2). (We previously observed low amounts
of endogenous SREBP precursors in sterol-deprived
SRD-12B cells (Rawson et al., 1998), which we attribute
to degradation of the precursor by pathways that are
independent of S1P and do not lead to release of the
NH2-terminal fragment.) When the SRD-12B cells ex-
pressed the KDEL-terminated S1P, SREBP-2 was cleaved
to the nuclear form (lane 3), and cleavage was not inhib-
ited by sterols (lane 4). Expression of the KDAS-termi-
nated S1P also restored SREBP-2 processing (lane 5),
but in this case the SREBP-2 cleavage was abolished
by sterols (lane 6).
Figure 5. Immunoblot Analysis of S1P in Transfected and Nontrans- To follow the fate of the expressed S1P in the perma-
fected CHO Cells
nent cell lines, we subjected aliquots of whole-cell ex-
(A) Membrane fractions were prepared from either transfected S1P-
tracts and culture medium to electrophoresis, followeddeficient SRD-12B cells (lanes 1 and 2) or nontransfected CHO/
by immunoblotting with an antibody against the MycpS2P cells (lane 3) as described in Experimental Procedures. SRD-
epitope tag (Figure 6C). As expected, we visualized no12B cells were transfected as described in Figure 2 with either 0.5
mg of pcDNA3 empty vector (lane 1) or pCMV-S1P (lane 2), and the Myc-tagged S1P in the parental SRD-12B cells (lanes 1
total amount of transfected DNA was adjusted to 3 mg/dish by the and 2). In the cells expressing the KDEL construct, we
addition of pcDNA3 empty vector. Transfected cells were incubated visualized all three forms (S1P-A, S1P-B, and S1P-C).
in medium A supplemented with 5% fetal calf serum for 16 hr prior In the cells expressing S1P-KDAS, we observed a strik-to harvest and cell fractionation. Aliquots of membrane protein (3
ingly different result. The cell extracts contained equiva-mg, lanes 1 and 2; 15 mg, lane 3) were subjected to SDS-PAGE and
lent amounts of S1P-A and S1P-B, but there was muchimmunoblotted with a 1:500 dilution of anti-S1P antiserum. Filter
was exposed to film for 10 s. less S1P-C than we observed in the cells expressing
(B) CHO/pS2P and SRD-12B cells were cultured in medium A sup- S1P-KDEL. Instead, we found S1P-C in the culture me-
plemented with 5% newborn calf lipoprotein-deficient serum and dium of the S1P-KDAS cells (lanes 5 and 6). Sterols had
compactin/mevalonate in the absence (lanes 1±5) or presence of no effect on the amount of S1P in either cell line. The
sterols (lanes 6±10) for 17 hr. Cells were harvested, and membrane
data of Figure 6 are consistent with the hypothesis thatfractions were prepared as described in the Experimental Proce-
S1P-KDEL is retained in the cells as a result of bindingdures. Aliquots of membrane protein (15 mg) were treated with the
to the KDEL receptor and retrieval to the ER from the Golgifollowing glycosidases: lanes 1, 2, 5, 6, 7, and 10, none; lanes 3 and
8, 0.26 IU/ml peptide N-glycosidase F (PNGase F); lanes 4 and 9, and that this retrieval leads to cleavage of SREBP-2 that
0.83 IU/ml endo H. Following enzymatic treatment, samples were cannot be blocked by sterols.
subjected to SDS-PAGE and immunoblotted with a 1:500 dilution The experiments of Figure 7 were designed to deter-
of anti-S1P antiserum. Filter was exposed to film for 15 s. mine whether S1P-KDEL obviates the requirement for
SCAP and to confirm that cleavage by S1P-KDEL re-
quires the RSVL recognition sequence in the luminal
transfect cells with a mutant form of S1P that contains loop of SREBP-2. For this purpose, we transfected
an ER retention/retrieval signal. For this purpose, we SCAP-deficient SRD-13A cells with a plasmid encoding
prepared a cDNA encoding S1P that was truncated just wild-type HSV-tagged SREBP-2 or a mutant version
prior to the COOH-terminal transmembrane domain (Fig- containing an Ala in place of the Arg of the S1P recogni-
ure 6A). Prior studies have shown that such a truncated tion sequence, RSVL (Figure 7A). In the absence of any
form of S1P is catalytically active (Cheng et al., 1999). cotransfected plasmid, the SRD-13A cells failed to gen-
At the COOH terminus, we inserted three copies of a erate the nuclear form of SREBP-2 (middle panel, lanes
Myc epitope tag followed by the sequence Lys-Asp- 2 and 3). Cotransfection of a plasmid encoding SCAP
Glu-Leu (KDEL). This mutant version of S1P should be restored SREBP-2 cleavage, and this was suppressed
inserted into the ER lumen. After it exits from the ER, it by sterols (lanes 4 and 5). Cotransfection of S1P-KDEL
should bind to the KDEL receptor, which should trans- also restored cleavage, and this was no longer sup-
port it back to the ER from the Golgi (Pelham, 1992). As pressed by sterols (lanes 6 and 7). The S1P-KDAS con-
a control, we prepared a similar construct containing struct was unable to restore cleavage in SRD-13A cells
the COOH-terminal sequence Lys-Asp-Ala-Ser (KDAS), (lanes 8 and 9). The S1P-KDEL plasmid did not stimulate
which is not recognized by the KDEL receptor (Munro cleavage of the R519A version of SREBP-2 (lanes 11
and 12). The bottom panel of Figure 7A shows thatand Pelham, 1987). We transfected these cDNAs into
Cell
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Figure 6. Stable Expression of S1P(1-997)
Myc-KDEL in S1P-Deficient SRD-12B Cells
Produces Unregulated Cleavage of SREBP-2
(A) Structure of S1P(1-997)Myc-KDEL and
S1P(1-997)Myc-KDAS. The propeptide (Pro)
and the subtilisin-like catalytic domain are
boxed. The signal sequence (ss), catalytic site
serine (Ser-414), Myc epitope tags, and the
COOH-terminal four amino acids (KDEL or
KDAS) are indicated. Amino acid numbers are
shown below the diagram.
(B) Cleavage of SREBP-2 in SRD-12B cells
stably transfected with pCMV-S1P(1-997)
Myc-KDEL. Clones of SRD-12B cells that sta-
bly express either S1P(1-997)Myc-KDEL or
S1P(1-997)Myc-KDAS were generated as de-
scribed in the Experimental Procedures.
SRD-12B cells (lanes 1 and 2) and SRD-12B
cells stably transfected with pCMV-S1P
(1-997)Myc-KDEL (lanes 3 and 4) or pCMV-
S1P(1-997)Myc-KDAS (lanes 5 and 6) were
cultured for 16 hr in medium A supplemented
with 5% newborn calf lipoprotein-deficient
serum and compactin/mevalonate in the ab-
sence or presence of sterols, and whole-cell
extracts were prepared as described in the Experimental Procedures. Aliquots of cell extract (65 mg protein) were subjected to SDS-PAGE
and immunoblotted with 5 mg/ml of monoclonal IgG-7D4 anti-SREBP-2. Filters were exposed to film for 5 s (top panel) and 30 s (bottom
panel). P and N denote the precursor and cleaved nuclear forms of SREBP-2, respectively.
(C) Secretion of S1P(1-997)Myc-KDEL or S1P(1-997)Myc-KDAS in stably transfected SRD-12B cells. SRD-12B cells (lanes 1 and 2) and SRD-
12B cells stably transfected with pCMV-S1P(1-997)Myc-KDEL (lanes 3 and 4) or pCMV-S1P(1-997)Myc-KDAS (lanes 5 and 6) were cultured
for 16 hr in medium A supplemented with 5% newborn calf lipoprotein-deficient serum and compactin/mevalonate in the absence or presence
of sterols. Samples of medium and whole-cell extracts were prepared as described in the Experimental Procedures. Aliquots of cell extracts
(40 mg protein) and medium (corresponding to an equivalent amount of cells) were subjected to SDS-PAGE and immunoblotted with 2.5 mg/
ml anti-Myc 9E10 antibody. Filters were exposed to film for 1 s. Molecular mass standards are expressed in kilodaltons.
S1P-C was detectable in membrane vesicles derived Three lines of evidence support these conclusions. First,
previous studies of SCAP glycosylation have shown thatfrom the cells expressing S1P-KDEL, but not S1P-KDAS.
Figure 7B shows a similar transient transfection ex- SCAP moves from the ER to the Golgi when cells are
grown in the absence, but not the presence of sterolsperiment in S1P-deficient SRD-12B cells. In the absence
of a cotransfected plasmid, these cells failed to generate (Nohturfft et al., 1998b, 1999). Second, S1P-C, the pre-
dominant form of active S1P, is found in or near thethe nuclear form of HSV-tagged SREBP-2 (middle panel,
lanes 2 and 3). Expression of wild-type S1P restored Golgi apparatus, as shown by immunocytochemistry
(Figures 3 and 4) and studies of glycosylation patternssterol-regulated cleavage (lanes 4 and 5). Expression of
S1P-KDEL also restored cleavage, but there was no (Figure 5). Third, retrograde transport of active S1P to
the ER by two independent methods elicits unregulatedsuppression by sterols (lanes 6 and 7). S1P-KDAS re-
stored cleavage to a lesser extent, and sterol suppres- SREBP processing and obviates the requirement for
SCAP in SRD-13A cells (see Figure 8B).sion was preserved (lanes 8 and 9). Neither S1P-KDEL
nor S1P-KDAS permitted cleavage of the R519A version The current findings with brefeldin A provide an expla-
nation for the earlier findings of Ridgway and Lagaceof SREBP-2 (lanes 11±14). Again, immunoblotting with
anti-Myc revealed abundant S1P-C in the cells express- (Ridgway and Lagace, 1995), who observed that brefel-
din A blocks sterol-mediated suppression of transcrip-ing S1P-KDEL, but much lower amounts in the cells
expressing S1P-KDAS (lower panel of Figure 7B). These tion in CHO cells. By redistributing active S1P from the
Golgi to the ER, brefeldin A eliminates the need to trans-data indicate that expression of S1P-KDEL in the ER
bypasses the SCAP requirement for SREBP cleavage. port SREBPs to the Golgi, allowing cleavage of SREBP
in the presence as well as absence of sterols. This con-
clusion is supported by the demonstration that a similarDiscussion
effect can be achieved by attaching a KDEL signal to
S1P, thereby trapping it in the ER.The current results support the hypothesis that cleavage
of SREBPs at Site-1 requires vesicular transport of The current studies also provide information about the
Site-2 protease (S2P), which cleaves the NH2-terminalSREBPs from the ER to the Golgi and that this transport
is blocked by sterols. The key to regulated transport is intermediate form of SREBPs that is produced by cleav-
age at Site-1. If Site-1 cleavage normally occurs in aSCAP, which forms a tight complex with SREBPs. In
sterol-depleted cells, SCAP escorts SREBP to a post- Golgi compartment, then S2P must also be located in
this compartment or a more distal compartment in theER compartment that contains active S1P (see model
in Figure 8A). In the presence of sterols, the SCAP/ secretory pathway. When Site-1 cleavage takes place
in the ER, as in brefeldin A±treated wild-type CHO cells,SREBP complex remains in the ER, and SREBP never
reaches the compartment that contains active S1P. it is followed by Site-2 cleavage, thereby generating the
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Figure 7. Transfected S1P(1-997)Myc-KDEL Rescues Cleavage of SREBP-2 in Cells Deficient in SCAP (A) and S1P (B)
(A) Immunoblot analysis of SREBP-2 cleavage in transfected SCAP-deficient SRD-13A cells. SRD-13A cells were set up on day 0 in medium
B at 4 3 105 cells/60 mm dish and transfected on day 1 as described in the Experimental Procedures. The indicated plasmid encoding either
wild-type (lanes 2±9) or mutant R519A (lanes 11±14) HSV-tagged SREBP-2 (1.75 mg/dish) was cotransfected into SRD-13A cells with empty
vector (lanes 1±3, and 10), pTK-SCAP (0.05 mg/dish; lanes 4 and 5), pCMV-S1P(1-997)Myc-KDEL (0.25 mg/dish; lanes 6, 7, 11, and 12), or
pCMV-S1P(1-997)Myc-KDAS (0.25 mg/dish; lanes 8, 9, 13, and 14) as indicated. The total amount of transfected DNA was adjusted to 3.75
mg/dish by the addition of pTK empty vector and pcDNA3 empty vector. Transfected cells were incubated for 18 hr in medium A supplemented
with 5% newborn calf lipoprotein-deficient serum and compactin/mevalonate in the absence or presence of sterols, and the cells were
harvested and fractionated as described in the Experimental Procedures. Aliquots of membranes (3 mg protein) and nuclear extract (15 mg
protein) were subjected to SDS-PAGE and immunoblotted with 0.5 mg/ml IgG-HSV-Tag antibody (top and middle panels) or 2.5 mg/ml anti-
Myc 9E10 antibody (bottom panel). Filters were exposed to film for 1 s. P and N denote the precursor and cleaved nuclear forms of SREBP-2,
respectively. Molecular mass standards are expressed in kilodaltons.
(B) Immunoblot analysis of SREBP-2 cleavage in transfected S1P-deficient SRD-12B cells. SRD-12B cells were set up on day 0 in medium B
at 4 3 105 cells/60 mm dish and transfected on day 1 as described in the Experimental Procedures. The indicated plasmid encoding either
wild-type (lanes 2±9) or mutant R519A (lanes 11±14) HSV-tagged SREBP-2 (1.75 mg/dish) was cotransfected into SRD-12B cells with empty
vector (lanes 1±3, and 10), pCMV-S1P-Myc (0.25 mg/dish; lanes 4 and 5), pCMV-S1P(1-997)Myc-KDEL (0.25 mg/dish; lanes 6, 7, 11, and 12),
or pCMV-S1P(1-997)Myc-KDAS (0.25 mg/dish; lanes 8, 9, 13, and 14) as indicated. The total amount of transfected DNA was adjusted to 3.75
mg/dish by the addition of pTK empty vector and pcDNA3 empty vector. Cells were cultured and harvested as described in (A). Aliquots of
membranes (4 mg protein) and nuclear extracts (11 mg protein) were subjected to SDS-PAGE and immunoblotted with 0.5 mg/ml IgG-HSV-
Tag antibody (top and middle panels) or 2.5 mg/ml anti-Myc 9E10 antibody (bottom panel). Filters were exposed to film for 1 s. P and N denote
the precursor and cleaved nuclear forms of SREBP-2, respectively. Molecular mass standards are expressed in kilodaltons.
nuclear form of SREBP (Figure 1). This implies either (Figures 6 and 7). In this case, Site-2 cleavage might
have been catalyzed by the fraction of active S2P thatthat some active S2P normally resides in the ER or that
S2P is translocated there along with S1P following bre- resides in the ER, or the cleaved intermediate form of
SREBP might have left the ER and reached the Golgifeldin A treatment. We also generated the nuclear form
of SREBP after cleavage by the KDEL-terminated S1P compartment where S2P resides.
Figure 8. A Model Illustrating the Requirement of SCAP for Cleavage of SREBPs
(A) Wild-type cells. In the absence of sterols, SCAP transports SREBPs to the Golgi where S1P cleaves SREBPs. Transport of SCAP is blocked
in the presence of sterols.
(B) SRD-13A cells (SCAP-deficient cells). In the absence of SCAP, SREBPs cannot gain access to active S1P, thus preventing cleavage (left
panel). Treatment of cells with brefeldin A translocates S1P from the Golgi to the ER, restoring cleavage of SREBPs (middle panel). Retrieval
of active, soluble S1P from the Golgi to the ER by the KDEL receptor also restores cleavage of SREBPs (right panel).
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If active S1P and S2P are both located in the same carrier vesicles that are targeted to a particular organ-
elle. This situation would be analogous to the functioncompartment, this compartment is in or near the Golgi,
as indicated by immunofluorescence studies (Figure 3). of cell surface clathrin-coated pits, which are common
carriers whose cargo is selected by sorting molecules.This compartment has the properties of the cis- or me-
dial-Golgi stacks in that it collapses into the ER following
treatment with brefeldin A (Figure 4). For this reason, Experimental Procedures
we refer to this compartment as the Golgi. However,
Materialsthis compartment may not be composed of classic Golgi
We obtained monoclonal anti-HSV-Tag (IgG1) from Novagen, mono-stacks. It might be part of the transitional network of
clonal anti-Myc (clone 9E10) from Roche Molecular Biochemicals,
tubules and vesicles that exists between the ER and horseradish peroxidase-conjugated donkey anti-mouse and anti-
Golgi. Further definition of the protease-containing com- rabbit IgG (affinity-purified) from Jackson Immunoresearch Labora-
partment awaits the development of antibodies capable tories, horseradish peroxidase-conjugated donkey anti-rabbit whole
antibody from Amersham Pharmacia Biotech, glycosidases fromof visualizing S2P in nontransfected cells that express
New England Biolabs, and brefeldin A from Calbiochem. The follow-physiologic amounts of this protein. Cell fractionation
ing recombinant expression plasmids were previously described:studies and ultrastructural analysis by electron micros-
pTK-HSV-BP2 (WT and R519A), encoding wild-type and mutant
copy are also required. HSV-tagged human SREBP-2 (Hua et al., 1996b); pTK-SCAP, encod-
Certain parallels exist between the role of SCAP in ing hamster SCAP (Nohturfft et al., 1998b); and pCMV-Myc-S1P,
SREBP processing and the role played by presenilin in pCMV-S1P-Myc, and pCMV-S1P, encoding hamster S1P (Espen-
shade et al., 1999). Other reagents were obtained from sources asthe processing of the amyloid precursor protein (APP),
described previously (Wang et al., 1994). Newborn and fetal calfwhich is the only other animal cell protein that is clearly
lipoprotein-deficient sera (d . 1.215 mg/ml) were prepared as de-shown to be cleaved within a transmembrane region
scribed (Goldstein et al., 1983).
(Selkoe, 1996). Presenilin, like SCAP, is a polytopic
membrane protein that is required for proteolytic pro- Cell Culture
cessing of APP (Haass and De Strooper, 1999). Some Cells were maintained in monolayer culture at 378C in 8%-9% CO2.
(Weidemann et al., 1997; Xia et al., 1997), but not all CHO-7 cells are a clone of CHO-K1 cells selected for growth in
lipoprotein-deficient serum (Metherall et al., 1989). CHO/pS2P cells(Thinakaran et al., 1998) studies show that presenilin
(Rawson et al., 1998) are a clone of CHO-7 cells stably transfectedforms a complex with full-length APP prior to proteolytic
with pCMV-HSV-S2P, a plasmid that encodes human Site-2 prote-cleavage. In addition, presenilin is necessary in order
ase under control of the cytomegalovirus (CMV) promoter enhancer.
for APP to be transported to the cellular compartment SRD-12B cells (deficient in Site-1 protease) and SRD-13A cells (defi-
where the g-secretase resides (Naruse et al., 1998). cient in SCAP) are previously described cholesterol and unsaturated
These findings have direct parallels with SCAP. A corol- fatty acid auxotrophs derived from g-irradiated CHO/pS2P cells
(Rawson et al., 1998, 1999). In experiments using SRD-12B or SRD-lary of this hypothesis is that the absence of presenilin
13A cells, the parental line, CHO/pS2P, was used as a control. Stockprevents APP from reaching the compartment where
cultures of CHO-7 cells were maintained in medium A (1:1 mixturethe g-secretase resides (Naruse et al., 1998). This is
of Ham's F12 medium and Dulbecco's modified Eagle medium con-
analogous to the fate of SREBP in SCAP-deficient cells. taining 100 U/ml penicillin and 100 mg/ml streptomycin sulfate) sup-
Although SCAP and presenilin share certain functions, plemented with 5% (v/v) newborn or fetal calf lipoprotein-deficient
the proteins have no sequence resemblance. Moreover, serum. Stock cultures of CHO/pS2P cells were maintained in me-
dium A supplemented with 5% fetal calf lipoprotein-deficient serum,they facilitate different reactions. SCAP facilitates the
2 mM compactin, and 500 mg/ml G418. Stock cultures of SRD-12Bfirst cleavage of SREBP, which occurs in the luminal
and SRD-13A cells were maintained in medium B (medium A supple-domain of SREBP. Presenilin facilitates the second
mented with 5% (v/v) fetal calf serum, 5 mg/ml cholesterol, 1 mM
cleavage of APP, namely the intramembrane cleavage sodium mevalonate, and 20 mM sodium oleate).
that follows the luminal cleavage. Indirect evidence sug-
gests that presenilin may be an aspartyl protease that Construction of pCMV-S1P(1-997)Myc-KDEL
cleaves APP at the g site (Wolfe et al., 1999). Like Site-2 and pCMV-S1P(1-997)Myc-KDAS
The expression vector pCMV-S1P(1-997)Myc-KDXX encodes aminoin SREBP, the g cleavage site of APP is located within a
acids 1-997 of hamster S1P followed by three tandem copies of thetransmembrane domain. However, there is no evidence
c-Myc epitope tag (GGRSEQKLISEEDLNGEQKLISEEDLNGEQKLIthat SCAP is a protease, and indeed we have isolated
SEEDLNSSGR) and the amino acids KDEL or KDAS under the controla protein with the characteristics of a hydrophobic zinc
of the CMV promoter enhancer. To generate these plasmids, we
metalloprotease that appears to carry out Site-2 cleav- used the QuikChange site-directed mutagenesis kit (Stratagene)
age of SREBPs (Rawson et al., 1997). to mutagenize pCMV-S1P (Sakai et al., 1998b) using the following
oligonucleotides: 59-GCCGCTACAACCAAGAGGGCGGCCGCAAGIn a more general sense, the results with SCAP and
GACGAGCTGTGATAAGTGGGCCAGACCATCCC-39 for the KDELpresenilin point out the important role of regulated vesic-
plasmid and 59-GCCGCTACAACCAAGAGGGCGGCCGCAAGGACular transport in carrying membrane proteins to their
GCCTCCTGATAAGTGGGCCAGACCATCCC-39 for the KDAS plas-
sites of processing. The postulated transport roles of mid. Following mutagenesis, a 120 bp fragment flanked by NotI sites
SCAP and presenilin raise the possibility that polytopic encoding three tandem copies of the c-Myc epitope (Sakai et al.,
membrane proteins may function as escort molecules 1998b) was inserted into the NotI site of the newly created plasmids.
In all plasmid constructions, mutations were confirmed by sequenc-that carry specific proteins to their sites of processing.
ing the relevant regions.Schekman and colleagues have postulated the exis-
tence of these molecular sorters in yeast (Springer et al.,
Stable Transfection of SRD-12B Cells1999). It will be important to determine whether escort
On day 0, cholesterol auxotrophic SRD-12B cells were plated at a
proteins like SCAP or presenilin target proteins to dedi- density of 4 3 105 cells/60 mm dish in medium B. On day 1, cells
cated vesicles, or whether they simply select individual were transfected with 0.5 mg of either pCMV-S1P(1-997)Myc-KDEL
or pCMV-S1P(1-997)Myc-KDAS plus 2.5 mg of pcDNA3 (Invitrogen)proteins for incorporation into a single set of common
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per dish using the lipofectamine method as described previously the SuperSignal CL-HRP substrate system (Pierce) according to the
manufacturer's instructions. Gels were calibrated with prestained(Sakai et al., 1998b). On day 2, the medium was switched to medium
A supplemented with 5% fetal calf lipoprotein-deficient serum (con- molecular mass markers (Bio-Rad). Filters were exposed to X-Omat
Blue XB-1 film (Kodak) at room temperature for the indicated times.taining no added cholesterol). The medium was changed as needed
for 12 days until individual colonies were visible. Stable expression
of either S1P(1-997)Myc-KDEL or S1P(1-997)Myc-KDAS permitted Glycosidase Sensitivity of S1P
growth of SRD-12B cells in the absence of exogenous cholesterol. SRD-12B and CHO/pS2P cells were cultured in medium A supple-
Single-cell clones that stably expressed S1P(1-997)Myc-KDEL and mented with 5% newborn calf lipoprotein-deficient serum, 50 mM
S1P(1-997)Myc-KDAS were isolated by limiting dilution and compactin, and 50 mM mevalonate in the absence or presence of
screened for S1P expression by immunoblotting with anti-Myc sterols (1 mg/ml 25-hydroxycholesterol plus 10 mg/ml cholesterol
(clone 9E10) monoclonal antibody. Two cell lines expressing equiva- added in a final concentration of 0.2% ethanol). After 16 hr, ALLN
lent levels of S1P(1-997)Myc-KDEL and S1P(1-997)Myc-KDAS were was added to a final concentration of 25 mg/ml, and the cells were
selected for further studies and designated S1P-KDEL and S1P- harvested 1 hr later. Membrane and nuclear extract fractions were
KDAS cells, respectively. prepared as described above. Aliquots of solubilized membrane
For experiments using SRD-12B stable cell lines, cells were set proteins (15 mg) were treated with either peptide N-glycosidase F
up on day 0 at a density of 7 3 105 cells/10 cm dish in medium B. or endoglycosidase H (endo H) as described previously (Sakai et
On day 1, the medium was switched to medium A supplemented al., 1998b).
with 5% newborn calf lipoprotein-deficient serum, 50 mM compactin,
and 50 mM sodium mevalonate in the absence or presence of sterols Indirect Immunofluorescence Microscopy
(1 mg/ml 25-hydroxycholesterol plus 10 mg/ml cholesterol added in CHO/pS2P and SRD-12B cells were set up on glass coverslips in
a final concentration of 0.2% ethanol). After 15 hr, N-acetyl-leucinal- medium B. Cells were washed in buffer C containing 0.1 M sodium
leucinal norleucinal (ALLN) was added to a final concentration of phosphate at pH 7.4, 0.15 M NaCl, 4 mM KCl, 2 mM MgCl2, and
25 mg/ml for 1 hr prior to harvest. To prepare whole-cell extracts, cell 0.02% (w/v) sodium azide and then fixed and permeabilized by
monolayers were washed three times in cold Dulbecco's phosphate- incubating for 10 min in solution containing 60% (v/v) methanol,
buffered saline containing 1 mM sodium EDTA and 1 mM sodium 10% (v/v) glacial acetic acid, and 30% (v/v) 1,1,1-trichloroethane.
EGTA. To lyse the cells, 0.25 ml of SDS lysis buffer containing 13 After a brief rinse with buffer C, cells were incubated for 30 min at
protease inhibitor cocktail (1 mM dithiothreitol, 1 mM PMSF, 0.5 room temperature in blocking buffer (0.1 M Tris±HCl at pH 9.0, 1%
mM Pefabloc, 10 mg/ml leupeptin, 5 mg/ml pepstatin A, 25 mg/ml [w/v] bovine serum albumin, 0.1 M NaCl, 0.02% [w/v] NaN3). Cells
ALLN, and 10 mg/ml aprotinin) was added to each dish. Cell lysate were incubated at 48C overnight with affinity-purified anti-S1P rabbit
was passed five times through a 22.5-gauge needle and five times polyclonal antibody (20 mg/ml in blocking buffer). Primary antibodies
though a 25-gauge needle. Whole-cell lysates were mixed with 53 were localized by incubating cells for 2 hr in 20 mg/ml affinity-puri-
SDS loading buffer and boiled for 5 min prior to SDS-PAGE. Aliquots fied, goat anti-rabbit IgG conjugated to Alexa 488 (Molecular Probes,
of the culture medium were collected, precipitated with acetone, Inc.) in blocking buffer. For Golgi compartment staining, rhodamine-
and resuspended in SDS lysis buffer as previously described (Es- labeled wheat germ agglutinin (Vector Laboratories, Inc.) was added
penshade et al., 1999). during the second antibody incubation at a concentration of 5 mg/
ml. Cells were washed three times after each antibody or lectin
Immunoblot Analysis of SREBP Processing incubation and analyzed with a Leica TCS SP confocal microscope.
On day 0, SRD-12B and SRD-13A cells were set up at the indicated S1P-specific antibodies were isolated from rabbit serum by affinity
density in medium B in 60 mm dishes. On day 1, cells were trans- chromatography using a cross-linked agarose resin conjugated to
fected with 4 mg of DNA/dish using 12 ml of Fugene 6 reagent (Roche the two immunizing synthetic peptides (Espenshade et al., 1999;
Molecular Biochemicals) in a final volume of 0.2 ml. Transfection Harlow and Lane, 1999). Peptides were conjugated to SulfoLink
was performed as previously described (Rawson et al., 1999). Cells Coupling Gel (Pierce) according to the manufacturer's instructions.
were incubated at 378C for 16±24 hr in medium A supplemented For the brefeldin A experiment, cells were treated with brefeldin A
with 5% fetal calf serum. On day 2, the medium was removed, and at a final concentration of 2 mg/ml in 0.2% methanol for 1 hr prior
the cells were cultured in medium A supplemented with 5% newborn to fixation of cells.
calf lipoprotein-deficient serum, 50 mM compactin, and 50 mM so-
dium mevalonate in the absence or presence of sterols (1 mg/ml
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